Skip to main content

Published locations for Obinutuzumab trends better than rituxumab in relapsed indolent lymphoma

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Obinutuzumab trends better than rituxumab in relapsed indolent lymphoma

User login

  • Reset your password
  • /content/obinutuzumab-trends-better-rituxumab-relapsed-indolent-lymphoma
  • /hematologynews/article/102437/indolent-lymphoma/obinutuzumab-trends-better-rituxumab-relapsed
  • /oncologypractice/article/102437/indolent-lymphoma/obinutuzumab-trends-better-rituxumab-relapsed
  • /hematologynews/nhlhub/article/102437/indolent-lymphoma/obinutuzumab-trends-better-rituxumab-relapsed
  • /hematology-oncology/article/102437/indolent-lymphoma/obinutuzumab-trends-better-rituxumab-relapsed
  • /b-cell-lymphoma-icymi/article/102437/indolent-lymphoma/obinutuzumab-trends-better-rituxumab-relapsed